Lisa Pilgram

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9742583/publications.pdf

Version: 2024-02-01

		1163117	1125743
11	200	8	13
papers	citations	h-index	g-index
15	15	15	351
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	First results of the "Lean European Open Survey on SARS-CoV-2-Infected Patients (LEOSS)― Infection, 2021, 49, 63-73.	4.7	62
2	Elevated markers of thrombo-inflammatory activation predict outcome in patients with cardiovascular comorbidities and COVID-19 disease: insights from the LEOSS registry. Clinical Research in Cardiology, 2021, 110, 1029-1040.	3.3	19
3	Prediction of COVID-19 deterioration in high-risk patients at diagnosis: an early warning score for advanced COVID-19 developed by machine learning. Infection, 2021, , 1.	4.7	18
4	Measles Virus Infection Fosters Dendritic Cell Motility in a 3D Environment to Enhance Transmission to Target Cells in the Respiratory Epithelium. Frontiers in Immunology, 2019, 10, 1294.	4.8	17
5	Gastrointestinal bleeding and endoscopic findings in critically and nonâ€critically ill patients with corona virus disease 2019 (COVIDâ€19): Results from Lean European Open Survey on SARSâ€CoVâ€2 (LEOSS) and COKA registries. United European Gastroenterology Journal, 2021, 9, 1081-1090.	3.8	17
6	Clinical course and predictive risk factors for fatal outcome of SARS-CoV-2 infection in patients with chronic kidney disease. Infection, 2021, 49, 725-737.	4.7	14
7	Outcomes of <scp>SARS oVâ€2</scp> Infections in Patients with Neurodegenerative Diseases in the <scp>LEOSS</scp> Cohort. Movement Disorders, 2021, 36, 791-793.	3.9	13
8	Specific Risk Factors for Fatal Outcome in Critically III COVID-19 Patients: Results from a European Multicenter Study. Journal of Clinical Medicine, 2021, 10, 3855.	2.4	12
9	All-cause mortality and disease progression in SARS-CoV-2-infected patients with or without antibiotic therapy: an analysis of the LEOSS cohort. Infection, 2021, 50, 423.	4.7	6
10	Angiotensin II receptor blocker intake associates with reduced markers of inflammatory activation and decreased mortality in patients with cardiovascular comorbidities and COVID-19 disease. PLoS ONE, 2021, 16, e0258684.	2.5	5
11	SARS-CoV-2 infection in chronic kidney disease patients with pre-existing dialysis: description across different pandemic intervals and effect on disease course (mortality). Infection, 2023, 51, 71-81.	4.7	1